Ashkan Golshani: A Step Closer to Developing a Therapeutic Against Platelet-type von Willebrand Disease
Ashkan Golshani, Professor at Carleton University, Co-founder of Designed Biologics, shared on LinkedIn:
”A step closer to developing a therapeutic against Platelet-type von Willebrand Disease (PT-VWD).
I am extremely proud of my team for developing the first-ever drug candidate against PT-VWD, a rare bleeding disorder (published in Blood Advances).
Using our state-of-the-art artificial intelligence-based drug development platform, my lab has developed a peptide that can reverse the phenotype of the mutant protein causing PT-VWD to its wild-type state.
Many thanks to my wonderful collaborators in this project Dr. Maha Othman and Paolo Gresele and all the members of my laboratory, past and present, especially Thomas Kazmirchuk, who spearheaded this project in my lab.
This work provides additional evidence for the applicability of our proprietary AI technology in developing novel therapeutics and diagnostics, moving us closer to replacing traditional monoclonal antibody development with AI-assisted method.”
Read the full article in Blood Advances.
Article: Developing an AI-Generated Peptide Targeting Platelet-type von Willebrand Disease
Authors: Thomas David Daniel Kazmirchuk, Jiashu Wang, Loredana Bury, Emanuela Falcinelli, Calvin Bradbury-Jost, Anastasiia Koziar, Mustafa Al-gafari, Sarah Takallou, William G Willmore, Frank Dehne, Paolo Gresele, Maha Othman, Ashkan Golshani
Stay updated on all scientific advances in the field of bleeding disorders with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia